卢马特佩龙的营销后安全问题:基于FDA不良事件报告系统 (FAERS) 数据库的药监测分析
Dan Zhao1, Wangxin Zhang2, Yan Liu1
1Department of Psychosomatic Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Frontiers in pharmacology
|May 24, 2024
概括
这项研究分析了FDA不良事件报告系统对卢马特的数据,揭示了125个不良事件信号,包括躁狂症和血清激素综合征. 医疗保健提供者应监测患者是否有潜在的精神病副作用.
科学领域:
- 药物监督 药物监督 药物监督
- 临床药理学 临床药理学
- 精神病学是一个精神病学.
背景情况:
- 卢马特佩龙是一种新型抗精神病药物,于2019年12月获得批准.
- 它的营销后不良事件概况需要进一步调查.
- 现实世界的安全数据对于理解其风险至关重要.
研究的目的:
- 通过使用现实世界的数据,探索lumateperone的潜在安全问题.
- 为了识别与lumateperone相关的不良事件信号.
- 为了补充现有的临床试验安全数据.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库的回顾性分析.
- 从2019年第四季度到2023年第三季度的lumateperone报告的数据提取.
- 使用报告几率比率 (ROR) 和贝叶斯信心传播神经网络 (BCPNN) 算法进行不成比例分析.
主要成果:
- 在26个系统器官类别中确定了125个不良事件信号.
- 108个信号是意想不到的,包括精神病事件,如躁狂和催眠症.
- 非精神病学信号包括尿和血清醇综合征.
结论:
- 这项研究提供了对lumateperone的基本现实安全数据.
- 医疗保健专业人员应该意识到双相抑郁症患者躁狂转变的风险.
- 需要进一步的流行病学研究来评估风险-益处概况.
相关概念视频
Pharmacovigilance
825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Antiepileptic Drugs: Potassium Channel Activators
173
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
173
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286


